Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
The molecular and antigenic properties of a Sabin-like type 2 poliovirus, isolated from the stool samples of a 2-year-old agammaglobulinaemic child who developed paralysis 1 year after receiving the third dose of oral poliovirus vaccine, were analysed. The virus revealed 0.88 % genome variation in the VP1 region compared with the standard reference strain, compatible with replication of the virus in the intestine over approximately 1 year. The typical mutations in the 5'NCR and VP1 associated with reversion to neurovirulence for Sabin type 2 poliovirus were found. Despite this, the virus was characterized by both PCR and ELISA tests as Sabin-like and showed temperature sensitivity and neurovirulence in transgenic mice typical of the Sabin type 2 vaccine strain. Gammaglobulin replacement therapy led rapidly to virus clearance, which, when combined with treatment with the antiviral drug pleconaril, stopped virus excretion; no further virus shedding occurred. This is the first case of poliomyelitis and long-term excretion from an immunodeficient patient to be reported in Italy through the active 'Acute Flaccid Paralysis' surveillance system.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The persistence of these viruses in immunocompromised individuals may compromise polio eradication efforts.”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [108]
Citations
Cites
RNA VIRUS MUTATIONS AND FITNESS FOR SURVIVAL
Domingo, E., & Holland, J. J. (1997) · Annual Review of Microbiology · doi:10.1146/annurev.micro.51.1.151 · Cited by 1,514 · cited 2×
“…have led to the selection of an attenuated variant, probably better adapted to replication in the gut, from a more neurovirulent virus population (Domingo & Holland, 1997); (iii) determinants that allow either high multiplication in the digestive tract or circulation of the virus do not…”
BackgroundKew, O., Morris-Glasgow, V., Landaverde, M., Burns, C., Shaw, J., Garib, Z., André, J., Blackman, E., Freeman, C. J., Jorba, J., et al. (2002) · Science · doi:10.1126/science.1068284 · Cited by 600 · cited 2×
“Even more worrying is the fact that VAPP outbreaks, reported recently in the Caribbean and the Philippines, have been caused by highly mutated and neurovirulent Sabin-like type 1 polioviruses (Kew et al., 2002; CDC, 2002a).”
BackgroundChronic Enteroviral Meningoencephalitis in Agammaglobulinemic Patients
McKinney, R. E., Katz, S. L., & Wilfert, C. M. (1987) · Clinical Infectious Diseases · doi:10.1093/clinids/9.2.334 · Cited by 452
Treatment of Potentially Life-Threatening Enterovirus Infections with Pleconaril
Rotbart, H. A., Webster, A. D., & for the Pleconaril Treatment Registry Group (2001) · Clinical Infectious Diseases · doi:10.1086/318452 · Cited by 373
Activity of Pleconaril against Enteroviruses
Pevear, D. C., Tull, T. M., Seipel, M. E., & Groarke, J. M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.9.2109 · Cited by 368 · cited 1×
“Pleconaril is an agent with activity against all enteroviruses (Pevear et al., 1999) and works by inhibiting the uncoating and release of infectious viral RNA, therefore blocking production of progeny virions (Rotbart, 1999).”
BackgroundHistory of Sabin attenuated poliovirus oral live vaccine strains
Sabin, A. B., & Boulger, L. R. (1973) · Journal of Biological Standardization · doi:10.1016/0092-1157(73)90048-6 · Cited by 319
Transgenic mice susceptible to poliovirus.
Koike, S., Taya, C., Kurata, T., Abe, S., Ise, I., Yonekawa, H., & Nomoto, A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.3.951 · Cited by 294
Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient
Kew, O. M., Sutter, R. W., Nottay, B. K., McDonough, M. J., Prevots, D. R., Quick, L., & Pallansch, M. A. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.10.2893-2899.1998 · Cited by 213 · cited 9×
“It is also important that all countries maintain high quality AFP and poliovirus surveillance and that a global strategy is developed for the cessation of immunization with OPV after global certification of polio eradication (WHO, 1997); before that, however, an adequate strategy to interrupt immunization with OPV mus…”
BackgroundInfluentialKilpatrick, D. R., Nottay, B., Yang, C. F., Yang, S. J., Mulders, M. N., Holloway, B. P., Pallansch, M. A., & Kew, O. M. (1996) · Journal of Clinical Microbiology · doi:10.1128/jcm.34.12.2990-2996.1996 · Cited by 172
Martín, J., Dunn, G., Hull, R., Patel, V., & Minor, P. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.7.3001-3010.2000 · Cited by 160 · cited 2×
“In fact, a delay in the accumulation of antigenic changes in these subjects has been observed (Martin et al., 2000).”
BackgroundMolecular epidemiology of polioviruses
Kew, O. M., Mulders, M. N., Lipskaya, G. Y., da Silva, E. E., & Patlansch, M. A. (1995) · Seminars in Virology · doi:10.1016/s1044-5773(05)80017-4 · Cited by 157 · cited 1×
“Based on the nucleotide change in VP1 between the isolate and the Sabin type 2 vaccine reference strain, the time between vaccine assumption and virus isolation was compatible with the mutation rate observed (Kew et al., 1995).”
ResultDeterminants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine
Bouchard, M. J., Lam, D. H., & Racaniello, V. R. (1995) · Journal of Virology · doi:10.1128/jvi.69.8.4972-4978.1995 · Cited by 140 · cited 2×
“Different animals such as monkeys and mice and various strains of normal and transgenic mice showed different sensitivity to certain attenuating mutations of Sabin type 1 poliovirus (reviewed by Bouchard et al., 1995).”
BackgroundBellmunt, A., May, G., Zell, R., Pring-Åkerblom, P., Verhagen, W., & Heim, A. (1999) · Virology · doi:10.1006/viro.1999.0003 · Cited by 128 · cited 2×
“OPV vaccination is therefore not advisable for immunodeficient people, as these people are also known to excrete poliovirus for long periods of time (Kew et al., 1998; Bellmunt et al., 1999; Minor, 2001).”
BackgroundLentz, K. N., Smith, A. D., Geisler, S. C., Cox, S., Buontempo, P. J., Skelton, A., DeMartino, J., Rozhon, E. J., Schwartz, J. L., GIRIJAVALLABHAN, V. M., et al. (1997) · Structure · doi:10.1016/s0969-2126(97)00249-9 · Cited by 123
Comparative study of five methods for intratypic differentiation of polioviruses
van der Avoort, H. G., Hull, B. P., Hovi, T., Pallansch, M. A., Kew, O. M., Crainic, R., Wood, D. J., Mulders, M. N., & van Loon, A. M. (1995) · Journal of Clinical Microbiology · doi:10.1128/jcm.33.10.2562-2566.1995 · Cited by 122 · cited 2×
“Intratypic differentiation was performed by PCR, using Sabin-specific primers (CDC, Atlanta, USA) (Kilpatrick et al., 1998), and ELISA, with cross-adsorbed type-specific polyclonal antibodies (van der Avoort et al., 1995).”
BackgroundMethodMinor, P. D., & Dunn, G. (1988) · Journal of General Virology · doi:10.1099/0022-1317-69-5-1091 · Cited by 120
Shulman, L. M., Manor, Y., Handsher, R., Delpeyroux, F., McDonough, M. J., Halmut, T., Silberstein, I., Alfandari, J., Quay, J., Fisher, T., et al. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.10.3729-3734.2000 · Cited by 109
Self-citationChristodoulou, C., Colbere-Garapin, F., Macadam, A., Taffs, L. F., Marsden, S., Minor, P., & Horaud, F. (1990) · Journal of Virology · doi:10.1128/jvi.64.10.4922-4929.1990 · Cited by 106
Kilpatrick, D. R., Nottay, B., Yang, C.-F., Yang, S.-J., Da Silva, E., Peñaranda, S., Pallansch, M., & Kew, O. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.2.352-357.1998 · Cited by 101
Martín, J., Samoilovich, E., Dunn, G., Lackenby, A., Feldman, E., Heath, A., Svirchevskaya, E., Cooper, G., Yermalovich, M., & Minor, P. D. (2002) · Journal of Virology · doi:10.1128/jvi.76.21.10921-10928.2002 · Cited by 86
Georgescu, M. M., Balanant, J., Macadam, A., Otelea, D., Combiescu, M., Combiescu, A. A., Crainic, R., & Delpeyroux, F. (1997) · Journal of Virology · doi:10.1128/jvi.71.10.7758-7768.1997 · Cited by 83 · cited 4×
“Strain S139C6, derived from a VAPP case, is a highly neurovirulent Sabin type 1 vaccine-derived strain, which has been shown to be as neurovirulent in Tg21 mice and also in monkeys as the wild type 1 poliovirus Mahoney reference strain (Christodoulou et al., 1990; Georgescu et al., 1997 ).”
BackgroundMethodSelf-citationComparative biochemical studies of type 3 poliovirus
Minor, P. D. (1980) · Journal of Virology · doi:10.1128/jvi.34.1.73-84.1980 · Cited by 79
Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine
Pollard, S. R., Dunn, G., Cammack, N., Minor, P. D., & Almond, J. W. (1989) · Journal of Virology · doi:10.1128/jvi.63.11.4949-4951.1989 · Cited by 76
Progress toward Global Polio Eradication
Hull, H. F., Birmingham, M. E., Melgaard, B., & Lee, J. W. (1997) · Journal of Infectious Diseases · doi:10.1093/infdis/175.supplement_1.s4 · Cited by 76
Statistical Aspects of Monitoring for Dangers in Drug Therapy)
Finney, D. J. (1971) · Methods of Information in Medicine · doi:10.1055/s-0038-1636028 · Cited by 51
Progress towards global polio eradication
Hull, H. F., & Aylward, R. B. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00144-x · Cited by 47
ANTIVIRAL THERAPY FOR ENTEROVIRAL INFECTIONS
Rotbart, H. A. (1999) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199907000-00013 · Cited by 42
Mutations in Sabin 2 Strain of Poliovirus and Stability of Attenuation Phenotype
Rezapkin, G. V., Fan, L., Asher, D. M., Fibi, M. R., Dragunsky, E. M., & Chumakov, K. M. (1999) · Virology · doi:10.1006/viro.1999.9718 · Cited by 40
Equestre, M., Genovese, D., Cavalieri, F., Fiore, L., Santoro, R., & Bercoff, R. P. (1991) · Journal of Virology · doi:10.1128/jvi.65.5.2707-2710.1991 · Cited by 27
Self-citationSurveillance of acute flaccid paralysis in Italy: 1996–1997
Fiore, L., Novello, F., Simeoni, P., Amato, C., Vellucci, L., Stefano, D. C. D., Grandolfo, M. E., & Luzzi, I. (1999) · European Journal of Epidemiology · doi:10.1023/a:1007697421114 · Cited by 17
Self-citationLonardo, A. D., Buttinelli, G., Amato, C., Novello, F., Ridolfi, B., & Fiore, L. (2002) · Journal of Virological Methods · doi:10.1016/s0166-0934(01)00437-2 · Cited by 17
Self-citationParalytic poliomyelitis in Italy (1981–85)
Novello, F., Lombardi, F., Amato, C., Santoro, R., Fiore, L., Grandolfo, M. E., & Pasquini, P. (1987) · European Journal of Epidemiology · doi:10.1007/bf00145073 · Cited by 15
Self-citationBiosafety consequences of eradication of wild-type polioviruses
Minor, P. D. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05399-5 · Cited by 15
Antigenic Variation of Poliovirus Studied by Means of Monoclonal Antibodies
Crainic, R., Blondel, B., & Horaud, F. (1984) · Clinical Infectious Diseases · doi:10.1093/clinids/6.supplement_2.s535 · Cited by 10
Antigenic Sites of Poliovirus Type 3 Eliciting IgA Monoclonal Antibodies in Orally Immunized Mice
Buttinelli, G., Ruggeri, F. M., Marturano, J., Novello, F., Donati, V., & Fiore, L. (2001) · Virology · doi:10.1006/viro.2000.0786 · Cited by 9
Self-citationPolio eradication--the last and toughest 1%.
Maurice, J. (2001) · Europe PMC (PubMed Central) · doi:10.1590/s0042-96862001000600020 · Cited by 7
Research works printed but not linked: 5
- 2002b, Public health dispatch: poliomyelitis, Madagascar, 2002, MMWR Morb Mortal Wkly Rep, 51, 622
- Ehrenfeld, 1995, Anatomy of the poliovirus 5′ NCR, Curr Top Microbiol Immunol, 203, 165
- Fiore, 2000, & 7 other authors and the Group for the Study of AFP, Ann Ig, 12, 99
- 1997, Manual for the Virologic Investigation of Poliomyelitis
- 2001, Polio Laboratory Manual
Cited by
Antiviral peptides as promising therapeutic drugs
Vilas Boas, L. C. P., Campos, M. L., Berlanda, R. L. A., de Carvalho Neves, N., & Franco, O. L. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03138-w · Cited by 336
Combelas, N., Holmblat, B., Joffret, M.-L., Colbère-Garapin, F., & Delpeyroux, F. (2011) · Viruses · doi:10.3390/v3081460 · Cited by 135
Self-citationIturriza‐Gómara, M., Megson, B., & Gray, J. (2005) · Journal of Medical Virology · doi:10.1002/jmv.20533 · Cited by 109
Halsey, N. A., Pinto, J. A., Espinosa-Rosales, F. J., Faure-Fontenla, M. A., da Silva, E., Khan, A. J., WEBSTER, A. D. B., Minor, P. D., Dunn, G., Asturias, E. J., et al. (2004) · Europe PMC (PubMed Central) · Cited by 106
Yang, C.-F., Chen, H.-Y., Jorba, J., Sun, H.-C., Yang, S.-J., Lee, H.-C., Huang, Y.-C., Lin, T.-Y., Chen, P.-J., Shimizu, H., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.20.12623-12634.2005 · Cited by 106
Metadata
- Authors
- Buttinelli, G., Donati, V., Fiore, S., Marturano, J., Plebani, A., Balestri, P., Soresina, A. R., Vivarelli, R., Delpeyroux, F., Martin, J., & Fiore, L.
- Affiliations
- Istituto Superiore di Sanità (IT)
- University of Brescia (IT)
- University of Siena (IT)
- Epidemiologie Moleculaire des Enterovirus, Institut Pasteur, Paris, France
- NIBSC, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK
- Venue
- Journal of General Virology
- Publisher
- Microbiology Society
- Published
- 2003-05-01
- Volume
- 84
- Issue
- 5
- Pages
- 1215-1221
- ISSN
- 0022-1317 (ISSN-L)
- 1465-2099
- OpenAlex
- W2101342567
- Cited by
- 73
- References
- 37
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 5 · 2023: 3 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 2 · 2017: 2 · 2016: 4 · 2015: 3 · 2014: 2 · 2013: 4 · 2012: 7
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of General Virology (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Health Sciences › Medicine › Infectious Diseases › Viral gastroenteritis research and epidemiology
- Keywords
- oral polio vaccine, immunodeficiency, vaccine-derived poliovirus, neurovirulence, VP1 mutations, 5' untranslated region, pleconaril, acute flaccid paralysis surveillance
- MeSH terms
- Agammaglobulinemia, Animals, Child, Preschool, Feces, Humans, Molecular Sequence Data, Poliomyelitis, Poliovirus Vaccine, Oral, Vaccines, Attenuated, Genetic Variation, Virulence, Sequence Analysis, DNA, Poliovirus, Amino Acid Substitution, 5' Untranslated Regions, Capsid Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.